Flapless Approach for the Treatment of Intrabony Defects

  • STATUS
    Recruiting
  • End date
    Apr 30, 2023
  • participants needed
    40
  • sponsor
    Istituto Ortopedico Galeazzi
Updated on 11 May 2022

Summary

The use of Enamel Matrix Derivative (EMD) associated to microsurgical flaps was demonstrated to be effective for the treatment of intrabony defects, in particular in presence of a self-contained anatomy. The main aim of this study will be to evaluate the difference in Clinical Attachment Level (CAL) between baseline and 1-year follow-up, comparing flapless periodontal regeneration using EMD versus the use of EMD after microsurgical flap elevation (Modified-Minimally Invasive Surgical Technique (M-MIST) / Single-flap approach).

Description

The secondary aims of the study are:

  • to evaluate the comparative effectiveness of the proposed treatment evaluating patient-centered outcomes.
  • to evaluate, after one year from the treatment, the comparative effectiveness evaluating clinical parameters: (I) Probing Depth (PD) measured from the gingival margin to the base of the pocket; (II) Recession (REC) measured as the distance between the CEJ and the gingival margin; (III) Presence of plaque in the site of intervention, measured dichotomously (Yes / No) (Plaque index (PI)); (IV) Presence of bleeding in the site of intervention, measured dichotomously (Yes / No) (Bleeding Index (BI)); (V) Full-mouth Bleeding Score (FMBS%); (VI) Full-mouth Plaque Score (FMPS%); (VII) the proportion of treated sites for each group that presented PD <= 3 mm. ; (VIII) tooth retention
  • to evaluate the comparative effectiveness evaluating radiographic parameters: (I) The distance between the Cemento-Enamel Junction (CEJ) and the bottom of the defect (CEJ-A) (II) the distance between the projection of the bone crest to the root surface and the bottom of the defect (representing the intrabony portion of the defect (III) C-A), and the distance between the bone crest and the root surface (representing the maximum width of the defect, C-B) were measured.

Control group: A buccal flap extending to the surfaces of the adjacent teeth will be elevated leading the interdental papilla in position following the M-MIST approach. After degranulation of the defect EMD will be applied following the standard procedure (after preparing root surface with Ethylenediamine tetraacetic acid (EDTA) 22% for two minutes). Non-resorbable 6/0 sutures will be used. The whole procedure will be performed using magnification devices (surgical loupes or surgical microscope). The operator will give postoperative instructions and information about medication.

Test group: The debridement of the pocket will be performed without the elevation of the flap, using ultrasonic tips, air polishing devices and curettes as standard procedure. After that, EMD will be applied and the same procedures as control group will be carried out. Non-resorbable 6/0 sutures will be used in the site of surgical intervention to close coronally the pocket.

At 7 days, suture removal, collection of questionnaires and clinical evaluation will be performed.

Follow-up visits will be carried out at 3, 6, 12, 18 and 24 months.

Details
Condition Intrabony Periodontal Defect
Treatment Enamel matrix derivative application for treatment of intrabony defects
Clinical Study IdentifierNCT05354037
SponsorIstituto Ortopedico Galeazzi
Last Modified on11 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Men and women over or equal to the age of 18 years
Patients who are able to understand the requirements of the study and are willing and able to comply with its instructions and schedules
Patients who had provided written informed consent to participate in the study prior to any study procedure
Patients in general good health in the opinion of the principal investigator as determined by medical history and clinical examination (American Society of Anesthesiologists ASA 1 or ASA-2)
Patients having one or more self-contained (3-wall or 2-3 walls) intrabony periodontal defect with an intrabony component of equal or more than 3 mm, as diagnosed by periapical radiographs and clinical evaluation

Exclusion Criteria

FMPS% > 15%
FMBS% > 15%
Treatment with anticoagulant drugs (International Normalized Ratio (INR) above 2,5)
Treatment with intravenous bisphosphonates
Treatment with anticonvulsants drugs
untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements
Patients with history of alcohol, narcotics or drug abuse
Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years
Patients through at any time received radiotherapy to the head and neck region will be excluded anyway
Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia
Degenerative diseases
Osteoradionecrosis
Renal failure
Organ transplant recipients
HIV positive (self-declaration)
Malignant diseases
Diseases that compromise the immune system
Unbalanced diabetes (HbA1c above 7.2 assessed by self-declaration)
Psychotic diseases
Hypersensitivity or specific contraindications to one of the components of EMD
Women who are pregnant (self-declaration); or lactating at the time of recruitment and of surgery
Site where a history of failed periodontal regenerative procedure in the last two years
Heavy Smokers (10 cigarettes and more per day)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note